Red Blood Cell Transfusion Thresholds and QOL in MDS (EnhanceRBC)
Myelodysplastic Syndromes (MDS), Quality of Life, Red Blood Cell (RBC) Transfusions
About this trial
This is an interventional treatment trial for Myelodysplastic Syndromes (MDS)
Eligibility Criteria
Inclusion Criteria:
- All patients with MDS ≥18 years of age
- Transfusion dependent: at least 1 transfusion per month in the last 8 weeks
- Hb <100g/L pre transfusion
- Life expectancy > 6 months
Exclusion Criteria:
- Unstable cardiac disease (Canadian Cardiovascular Society (CCS) III/IV angina or New York Heart Association (NYHA) III/IV congestive heart failure) requiring the transfusion target range to remain >85-100 g/L at all times
- ECOG ≥3
- Patients with red cell antibodies against high frequency antigens or multiple antibodies (would potentially delay finding blood)
- Patients on ESA's or disease modifying agents (like azacitidine) for their MDS
Sites / Locations
- Juravinski Cancer CentreRecruiting
- Princess Margaret HospitalRecruiting
- Sunnybrook Health Sciences Centre/Odette Cancer CentreRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Liberal transfusion strategy
Restrictive transfusion strategy
Intervention: Red Blood Cell transfusions. Transfuse pRBC at a higher threshold- maintain Hb level between 110 and 120 g/L: to achieve this, 2 units of pRBCs are transfused when Hb level is < 105 g/L and 1 unit of RBCs when Hb level is 105-110 g/L. Transfusions administered more frequently.
Intervention: Red Blood Cell transfusions. Transfuse pRBC at standard of care thresholds- maintain Hb level between 85 and 100 g/L: to achieve this, 2 units of packed red blood cells (pRBCs) will be transfused when the Hb level is < 80 g/L and 1 unit of pRBCs when Hb level is 80-85 g/L: standard administration